Corticorelin ovine triflutate
Acthrel (corticorelin ovine triflutate) is a protein pharmaceutical. Corticorelin ovine triflutate was first approved as Acthrel on 1996-05-23.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Corticorelin ovine triflutate
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Acthrel | corticorelin ovine triflutate | Ferring Pharmaceuticals Inc. | N-20162 DISCN | 1996-05-23 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
acthrel | Biologic Licensing Application | 2020-06-09 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
corticorelin ovine triflutate, Acthrel, Ferring Pharmaceuticals Inc. | |||
2103-05-23 | Orphan excl. |
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code | Description |
---|---|
J0795 | Injection, corticorelin ovine triflutate, 1 microgram |
Clinical
Clinical Trials
87 clinical trials
View more details

Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Dupuytren contracture | D004387 | EFO_0004229 | M72.0 | 1 | 2 | 12 | 8 | 5 | 28 |
Penile induration | D010411 | N48.6 | — | 2 | 5 | 3 | 2 | 12 | |
Diabetic foot | D017719 | EFO_1001459 | 1 | — | — | 8 | — | 9 | |
Cellulite | D000071697 | 1 | 5 | — | 1 | — | 7 | ||
Pressure ulcer | D003668 | L89 | — | — | 1 | 2 | 1 | 4 | |
Cicatrix | D002921 | HP_0100699 | L90.5 | — | — | — | 1 | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Bursitis | D002062 | EFO_1000941 | M71.9 | — | 3 | — | — | — | 3 |
Lipoma | D008067 | D17.9 | — | 2 | — | — | — | 2 | |
Urethral stricture | D014525 | HP_0012227 | N35 | — | 1 | — | — | — | 1 |
Contracture | D003286 | EFO_0003899 | M62.4 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Wounds and injuries | D014947 | T14.8 | — | — | — | — | 2 | 2 | |
Wound healing | D014945 | GO_0042060 | — | — | — | — | 1 | 1 | |
Burns | D002056 | T30.0 | — | — | — | — | 1 | 1 | |
Intervertebral disc displacement | D007405 | EFO_1001800 | — | — | — | — | 1 | 1 | |
Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | CORTICORELIN OVINE TRIFLUTATE |
INN | — |
Description | Acthrel (corticorelin ovine triflutate) is a protein pharmaceutical. Corticorelin ovine triflutate was first approved as Acthrel on 1996-05-23. |
Classification | Protein |
Drug class | prehormones or hormone-release stimulating peptides; vinca alkaloids |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
PDB | — |
CAS-ID | 121249-14-7 |
RxCUI | 74670 |
ChEMBL ID | CHEMBL1201591 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB09067 |
UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 33 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions

Mock data
Subscribe for the real data
Subscribe for the real data
4,232 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more